You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
德琪醫藥-B(06996.HK):澳大利亞藥品管理局確認ATG-022用於治療晚期或轉移性實體瘤的I期臨牀試驗的臨牀試驗通知
格隆匯 02-01 20:08

格隆匯2月1日丨德琪醫藥-B(06996.HK)公吿,公司董事會欣然宣佈,ATG-022用於治療晚期或轉移性實體瘤患者的首次臨牀試驗(CLINCH試驗)的申請已獲得悉尼Bellberry人類研究倫理委員會批准,澳大利亞藥品管理局已於2023年1月30日確認了該項目的臨牀試驗通知。CLINCH試驗目前已獲准在澳大利亞開展,並將在近期內啟動。

此為公司刊發的自願公吿。集團不能保證ATG-022最終能成功開發並銷售。公司股東及潛在投資者於買賣公司股份時務請審慎行事。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account